Anti-ENL Antibody (34043)

Maltose-binding fusion protein containing ENL amino acids 414-472 (Accession no. NP_005925).

This monoclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.2 - 7.4 with no carrier protein or preservatives added.

Liquid

Antibodies are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Upon initial thawing, appropriately aliquot and store at -80°C. For long-term storage, keep at -80°C. Avoid repeated freeze-thaw cycles.

Next Day 2-8°C

This antibody recognizes human ENL.

The AF4 and ENL (Eleven nineteen Leukemia) protein families are the most frequent MLL fusion partners accounting for two-thirds of MLL-associated leukemia incidence. The ENL family includes ENL and AF9 and has structural homology to the yeast Anc1 protein. ENL is a nuclear protein that is capable of activating transcription from synthetic reporter genes in both lymphoid and myeloid cells as well as in yeast. Deletion muta-genesis demonstrated that the minimal portion of ENL required for activation of transcription was localized to its C-terminal 90 amino acids. This region is highly conserved between ENL and AF9 and is retained in all Hrx-ENL and Hrx-AF9 fusion proteins. Thus, the leukemogenic contribution and transcriptional activation potential of ENL colocalize to its highly conserved carboxy terminus.

Chromatin reader component of the super elongation complex (SEC), a complex required to increase the catalytic rate of RNA polymerase II transcription by suppressing transient pausing by the polymerase at multiple sites along the DNA (PubMed:20159561, PubMed:20471948). Specifically rPubMed:20159561, PubMed:20471948, PubMed:27105114}.; Acts as a key chromatin reader in acute myeloid leukemia by rPubMed:28241139, PubMed:28241141}.

1) Rubnitz JE et al. 1994 Blood 84: 1747-1752.
2) Yokoyama A et al. 2010 Cancer Cell 17: 198-212.
3) Mueller D at al. 2007 Blood 110: 4445-4454.